{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:10:28Z","timestamp":1791328228663,"version":"4.3.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T00:00:00Z","timestamp":1667520000000},"content-version":"vor","delay-in-days":1525,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Fondazione Telethon","doi-asserted-by":"publisher","award":["GGP17106"],"award-info":[{"award-number":["GGP17106"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007365","name":"Fondazione IRCCS Policlinico San Matteo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1111\/jth.14217","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T02:18:22Z","timestamp":1530238702000},"page":"1700-1710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Thrombopoietin receptor agonists in hereditary thrombocytopenias"],"prefix":"10.1016","volume":"16","author":[{"given":"F.","family":"Rodeghiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pecci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Balduini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.14217_bb0010","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3109\/09537104.2016.1148806","article-title":"Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan","volume":"27","author":"Johnson","year":"2016","journal-title":"Platelets"},{"key":"10.1111\/jth.14217_bb0015","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/jth.12196","article-title":"Inherited thrombocytopenias frequently diagnosed in adults","volume":"11","author":"Balduini","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14217_bb0020","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5482\/ha12050001","article-title":"Inherited thrombocytopenias","volume":"32","author":"Balduini","year":"2012","journal-title":"H\u00e4mostaseologie"},{"key":"10.1111\/jth.14217_bb0025","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3324\/haematol.2015.138149","article-title":"Innovation in the field of thrombocytopenias: achievements since the beginning of the century and promises for the future","volume":"101","author":"Balduini","year":"2016","journal-title":"Haematologica"},{"key":"10.1111\/jth.14217_bb0030","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1111\/jth.13855","article-title":"Inherited thrombocytopenia caused by ANKRD26 mutations misdiagnosed and treated as myelodysplastic syndrome: report on two cases","volume":"15","author":"Zaninetti","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14217_bb0035","series-title":"PROMACTA [package insert]","year":"2017"},{"key":"10.1111\/jth.14217_bb0040","series-title":"Revolade (eltrombopag). [summary of product characteristics]","year":"2015"},{"key":"10.1111\/jth.14217_bb0045","series-title":"Nplate (romiplostim). [package insert]","year":"2017"},{"key":"10.1111\/jth.14217_bb0050","series-title":"Nplate (romiplostim). [summary of product characteristics]","year":"2013"},{"key":"10.1111\/jth.14217_bb0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/asheducation-2017.1.385","article-title":"Hereditary thrombocytopenias: a growing list of disorders","volume":"2017","author":"Noris","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1111\/jth.14217_bb0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00277-017-2953-6","article-title":"Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists","volume":"96","author":"Rodeghiero","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.14217_bb0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long\u2010term, open\u2010label EXTEND study","volume":"121","author":"Saleh","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0070","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonzalez\u2010Lopez","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.14217_bb0075","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14217_bb0080","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0085","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1111\/jth.14217_bb0090","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1182\/blood-2012-11-465575","article-title":"No cross\u2010resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura","volume":"121","author":"D'Arena","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0095","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00277-016-2896-3","article-title":"Sequential treatment with thrombopoietin\u2010receptor agonists (TPO\u2010RAs) in immune thrombocytopenia (ITP): experience in our center","volume":"96","author":"Gonz\u00e1lez","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.14217_bb0100","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.3324\/haematol.2016.146746","article-title":"Revealing eltrombopag's promotion of human megakaryopoiesis through AKT\/ERK\u2010dependent pathway activation","volume":"101","author":"Di Buduo","year":"2016","journal-title":"Haematologica"},{"key":"10.1111\/jth.14217_bb0105","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/humu.9415","article-title":"MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease","volume":"27","author":"Germeshausen","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1111\/jth.14217_bb0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.exphem.2010.02.007","article-title":"F104S c\u2010Mpl responds to a transmembrane domain\u2010binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents","volume":"38","author":"Fox","year":"2010","journal-title":"Exp Hematol"},{"key":"10.1111\/jth.14217_bb0115","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12185-013-1351-7","article-title":"Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin\u2010receptor agonists","volume":"98","author":"Pecci","year":"2013","journal-title":"Int J Hematol"},{"key":"10.1111\/jth.14217_bb0120","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0125","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2141.2011.08716.x","article-title":"Recent advances in the understanding and management of MYH9\u2010related inherited thrombocytopenias","volume":"154","author":"Balduini","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14217_bb0130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/humu.22476","article-title":"MYH9\u2010related disease: a novel prognostic model to predict the clinical evolution of the disease based on genotype\u2013phenotype correlations","volume":"35","author":"Pecci","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1111\/jth.14217_bb0135","doi-asserted-by":"crossref","first-page":"5832","DOI":"10.1182\/blood-2010-08-304725","article-title":"Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations","volume":"116","author":"Pecci","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0140","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1160\/TH12-01-0005","article-title":"Short\u2010term eltrombopag for surgical preparation of a patient with inherited thrombocytopenia deriving from MYH9 mutation","volume":"107","author":"Pecci","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14217_bb0145","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1542\/peds.2012-3807","article-title":"First successful use of eltrombopag before surgery in a child with MYH9\u2010related thrombocytopenia","volume":"132","author":"Favier","year":"2013","journal-title":"Pediatrics"},{"key":"10.1111\/jth.14217_bb0150","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1213\/XAA.0000000000000621","article-title":"Eltrombopag to treat thrombocytopenia during last month of pregnancy in a woman with MYH9\u2010related disease: a case report","volume":"10","author":"Favier","year":"2018","journal-title":"A A Pract"},{"key":"10.1111\/jth.14217_bb0155","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1160\/TH11-07-0474","article-title":"A patient with Fechtner syndrome successfully treated with romiplostim","volume":"107","author":"Gropper","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.14217_bb0160","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s00277-015-2416-x","article-title":"A novel MYH9 mutation in a patient with MYH9 disorders and platelet size\u2010specific effect of romiplostim on macrothrombocytopenia","volume":"94","author":"Yamanouchi","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.14217_bb0165","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0092-8674(94)90528-2","article-title":"Isolation of a novel gene mutated in Wiskott\u2013Aldrich syndrome","volume":"78","author":"Derry","year":"1994","journal-title":"Cell"},{"key":"10.1111\/jth.14217_bb0170","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/nyas.12049","article-title":"Wiskott\u2013Aldrich syndrome: a comprehensive review","volume":"1285","author":"Massaad","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/jth.14217_bb0175","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott\u2013Aldrich syndrome\/X\u2010linked thrombocytopenia","volume":"126","author":"Gerrits","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0180","doi-asserted-by":"crossref","first-page":"e26692","DOI":"10.1002\/pbc.26692","article-title":"Eltrombopag use in a patient with Wiskott\u2013Aldrich syndrome","author":"Gabelli","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1111\/jth.14217_bb0185","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/bjh.14694","article-title":"A new form of inherited thrombocytopenia due to monoallelic loss of function mutation in the thrombopoietin gene","volume":"181","author":"Noris","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14217_bb0190","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/blood-2012-12-473538","article-title":"Exome sequencing reveals a thrombopoietin ligand mutation in a Micronesian family with autosomal recessive aplastic anemia","volume":"122","author":"Dasouki","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0195","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2017-02-768036","article-title":"Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin","volume":"130","author":"Seo","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0200","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15252\/emmm.201708168","article-title":"Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim","volume":"10","author":"Pecci","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1111\/jth.14217_bb0205","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1182\/blood-2011-02-336537","article-title":"Mutations in ANKRD26 are responsible for a frequent form of inherited thrombocytopenia: analysis of 78 patients from 21 families","volume":"117","author":"Noris","year":"2011","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0210","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1080\/09537104.2016.1190446","article-title":"Successful use of eltrombopag for surgical preparation in a patient with ANKRD26\u2010related thrombocytopenia","volume":"27","author":"Fiore","year":"2016","journal-title":"Platelets"},{"key":"10.1111\/jth.14217_bb0215","unstructured":"ClinicalTrials.gov. Eltrombopag for inherited thrombocytopenias. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02422394. Accessed 10 May 2018."},{"key":"10.1111\/jth.14217_bb0220","unstructured":"Zaninetti C, Fierro T, Bertomoro A, Alberelli M, Veneri D, Bozzi V, Barozzi S, Noris P, De Candia E, Minuz P, Fabris F, Gresele P, Balduini CL, Pecci A. Short\u2010 and long\u2010term eltrombopag for the treatment of inherited thrombocytopenias: a phase 2 clinical trial. Abstract Book of the 23rd Congress of the European Hematology Association; 2018 June 14\u201317; Stockholm, Sweden. Haematologica, Forthcoming 2018."},{"key":"10.1111\/jth.14217_bb0225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0382-y","article-title":"5\u2032UTR point substitutions and N\u2010terminal truncating mutations of ANKRD26 in acute myeloid leukemia","volume":"10","author":"Marconi","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1111\/jth.14217_bb0230","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1101\/gad.1239604","article-title":"Tel\/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival","volume":"18","author":"Hock","year":"2004","journal-title":"Genes Dev"},{"key":"10.1111\/jth.14217_bb0235","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S1470-2045(15)00369-1","article-title":"Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study","volume":"16","author":"Moriyama","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1111\/jth.14217_bb0240","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ng.3253","article-title":"Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia","volume":"47","author":"Noetzli","year":"2015","journal-title":"Nat Genet"},{"key":"10.1111\/jth.14217_bb0245","doi-asserted-by":"crossref","first-page":"e1005262","DOI":"10.1371\/journal.pgen.1005262","article-title":"Germline ETV6 mutations confer susceptibility to acute lymphoblastic leukemia and thrombocytopenia","volume":"11","author":"Topka","year":"2015","journal-title":"PLoS Genet"},{"key":"10.1111\/jth.14217_bb0250","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng.3177","article-title":"Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy","volume":"47","author":"Zhang","year":"2015","journal-title":"Nat Genet"},{"key":"10.1111\/jth.14217_bb0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3324\/haematol.2016.147694","article-title":"Germline variants in ETV6 underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34+ progenitors","volume":"102","author":"Poggi","year":"2017","journal-title":"Haematologica"},{"key":"10.1111\/jth.14217_bb0260","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/jth.12131","article-title":"Transcription factors in late megakaryopoiesis and related platelet disorders","volume":"11","author":"Tijssen","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.14217_bb0265","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/bjh.13088","article-title":"Safety and efficacy of thrombopoietin\u2010receptor agonists in myelodysplastic syndromes: a systematic review and meta\u2010analysis of randomized controlled trials","volume":"167","author":"Prica","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1111\/jth.14217_bb0270","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower\u2010risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.14217_bb0275","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28663","article-title":"Results of a randomized, double\u2010blind study of romiplostim versus placebo in patients with low\/intermediate\u20101\u2010risk myelodysplastic syndrome and thrombocytopenia","volume":"120","author":"Giagounidis","year":"2014","journal-title":"Cancer"},{"key":"10.1111\/jth.14217_bb0280","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1182\/blood.V126.23.2863.2863","volume":"126","author":"Kantarjian","year":"2015","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0285","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(17)30012-1","article-title":"Eltrombopag versus placebo for low\u2010risk myelodysplastic syndromes with thrombocytopenia (EQoL\u2010MDS): phase 1 results of a single\u2010blind, randomised, controlled, phase 2 superiority trial","volume":"4","author":"Oliva","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1111\/jth.14217_bb0290","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/S2352-3026(15)00149-0","article-title":"Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo\u2010controlled, double\u2010blind, phase 1\/2 trial","volume":"2","author":"Platzbecker","year":"2015","journal-title":"Lancet Haematol"},{"issue":"s1","key":"10.1111\/jth.14217_bb0295","first-page":"15","article-title":"Thrombopoietin receptor agonist eltrombopag for advanced MDS or AML and severe thrombocytopenia: 12\u2010week, randomized, placebo\u2010controlled, phase 2 ASPIRE study","volume":"101","author":"Mittelman","year":"2016","journal-title":"Haematologica"},{"key":"10.1111\/jth.14217_bb0300","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0145-2126(17)30150-9","article-title":"Eltrombopag in combination with azacitidine for first\u2010line treatment of MDS patients with thrombocytopenia: the randomized, placebo\u2010controlled, phase III, support study","volume":"55","author":"Dickinson","year":"2017","journal-title":"Leuk Res"},{"key":"10.1111\/jth.14217_bb0305","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/jcph.113","article-title":"Iron chelation in the treatment of cancer: a new role for deferasirox?","volume":"53","author":"Bedford","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/jth.14217_bb0310","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1182\/blood-2009-04-219493","article-title":"Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"114","author":"Will","year":"2009","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0315","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1182\/blood-2011-12-399667","article-title":"Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation","volume":"120","author":"Roth","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0320","doi-asserted-by":"crossref","first-page":"e0126691","DOI":"10.1371\/journal.pone.0126691","article-title":"Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival","volume":"10","author":"Kalota","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1111\/jth.14217_bb0325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14217_bb0330","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.14217_bb0335","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0340","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.14217_bb0345","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/bloodadvances.2017007989","article-title":"ITP and thrombosis: an intriguing association","volume":"1","author":"Rodeghiero","year":"2017","journal-title":"Blood Adv"},{"key":"10.1111\/jth.14217_bb0350","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long\u2010term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0355","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000320335","article-title":"MYH\u20109 related platelet disorders: strategies for management and diagnosis","volume":"37","author":"Althaus","year":"2010","journal-title":"Transfus Med Hemother"},{"key":"10.1111\/jth.14217_bb0360","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study","volume":"90","author":"Brynes","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.14217_bb0365","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000452992","article-title":"A 2\u2010year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol"},{"key":"10.1111\/jth.14217_bb0370","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/ejh.12181","article-title":"Long\u2010term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials","volume":"91","author":"Rodeghiero","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1111\/jth.14217_bb0375","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1111\/jth.14217_bb0380","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1182\/blood-2010-05-286534","article-title":"Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p","volume":"116","author":"Gunay\u2010Aygun","year":"2010","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0385","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood-2013-04-499491","article-title":"Abnormal megakaryocyte development and platelet function in Nbeal2\u2212\/\u2212 mice","volume":"122","author":"Kahr","year":"2013","journal-title":"Blood"},{"key":"10.1111\/jth.14217_bb0390","doi-asserted-by":"crossref","first-page":"328ra30","DOI":"10.1126\/scitranslmed.aad7666","article-title":"A dominant gain\u2010of\u2010function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies","volume":"8","author":"Turro","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1111\/jth.14217_bb0395","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3324\/haematol.2011.050682","article-title":"Clinical and laboratory features of 103 patients from 42 Italian families with inherited thrombocytopenia derived from the monoallelic Ala156Val mutation of GPIb\u03b1 (Bolzano mutation)","volume":"97","author":"Noris","year":"2012","journal-title":"Haematologica"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.14217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622023546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622023546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.14217\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:22:03Z","timestamp":1761535323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622023546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1538783622023546"],"URL":"https:\/\/doi.org\/10.1111\/jth.14217","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombopoietin receptor agonists in hereditary thrombocytopenias","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.14217","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}